Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses the nutrient profile and potential health benefits of pumpkin and watermelon seeds, concluding they are underutilized and could be developed into various nutraceuticals.

This review discusses various herbal therapies, such as Serenoa repens and Pygeum africanum, for treating benign prostatic hyperplasia, noting their potential but highlighting unresolved questions about their efficacy and safety.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This study found a positive correlation between androgenetic alopecia severity and enlarged prostate size, with more severe cases showing a higher likelihood of prostate enlargement.

This study found that red ginseng oil (RXGIN) significantly improved lower urinary tract symptoms and some aspects of sexual function in men, with no serious adverse events reported.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

In this study, paternal exposure to finasteride prior to or during pregnancy was linked to a majority of normal full-term births, although some cases resulted in abortions, aligning with previous animal study findings.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.

This review reported that while finasteride is effective for treating androgenetic alopecia and benign prostatic hyperplasia, it may cause adverse effects such as sexual dysfunction and psychological symptoms, which require careful patient education and management to ensure treatment adherence and satisfaction.

In this study, the n-hexane fraction of Carthamus oxyacantha methanolic extract exhibited significant 5α-reductase inhibitory activity in vitro, suggesting potential therapeutic use for benign prostatic hyperplasia through DHT inhibition.